Difference between revisions of "Glypican 3"
Jump to navigation
Jump to search
(create) |
|||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Glypican 3''' is a common [[immunostain]] used in [[gastrointestinal pathology]] and [[ | '''Glypican 3''', abbreviated '''GPC3''',<ref>{{OMIM|300037}}</ref> is a common [[immunostain]] used in [[gastrointestinal pathology]] and [[genitourinary pathology]]. | ||
==Positive== | ==Positive== | ||
*[[Hepatocellular carcinoma]].<ref name=pmid25896897>{{Cite journal | last1 = Aydin | first1 = O. | last2 = Yildiz | first2 = L. | last3 = Baris | first3 = S. | last4 = Dundar | first4 = C. | last5 = Karagoz | first5 = F. | title = Expression of Glypican 3 in low and high grade urothelial carcinomas. | journal = Diagn Pathol | volume = 10 | issue = | pages = 34 | month = | year = 2015 | doi = 10.1186/s13000-015-0266-4 | PMID = 25896897 }}</ref> | *[[Hepatocellular carcinoma]].<ref name=pmid25896897>{{Cite journal | last1 = Aydin | first1 = O. | last2 = Yildiz | first2 = L. | last3 = Baris | first3 = S. | last4 = Dundar | first4 = C. | last5 = Karagoz | first5 = F. | title = Expression of Glypican 3 in low and high grade urothelial carcinomas. | journal = Diagn Pathol | volume = 10 | issue = | pages = 34 | month = | year = 2015 | doi = 10.1186/s13000-015-0266-4 | PMID = 25896897 }}</ref> | ||
*[[Malignant melanoma]].<ref name=pmid25896897/> | |||
*[[Squamous cell carcinoma of the lung]].<ref name=pmid25896897/> | |||
**Uncommon in adenocarcinoma of the lung ~3% of cases.<ref name=pmid26345955>{{Cite journal | last1 = Yu | first1 = X. | last2 = Li | first2 = Y. | last3 = Chen | first3 = SW. | last4 = Shi | first4 = Y. | last5 = Xu | first5 = F. | title = Differential expression of glypican-3 (GPC3) in lung squamous cell carcinoma and lung adenocarcinoma and its clinical significance. | journal = Genet Mol Res | volume = 14 | issue = 3 | pages = 10185-92 | month = Aug | year = 2015 | doi = 10.4238/2015.August.28.2 | PMID = 26345955 }}</ref> | |||
*[[Yolk sac tumour]]. | |||
**More sensitive than [[alpha-fetoprotein]] (AFP).<ref name=pmid20438407>{{Cite journal | last1 = Emerson | first1 = RE. | last2 = Ulbright | first2 = TM. | title = Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers. | journal = Pathology | volume = 42 | issue = 4 | pages = 344-55 | month = Jun | year = 2010 | doi = 10.3109/00313021003767355 | PMID = 20438407 }}</ref> | |||
===Images=== | |||
*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414302/figure/Fig1/ Glypican 3 in UCC (nih.gov)].<ref name=pmid25896897/> | |||
==Positive or negative== | |||
*[[Choriocarcinoma]]. | |||
==See also== | ==See also== | ||
Latest revision as of 16:29, 7 December 2017
Glypican 3, abbreviated GPC3,[1] is a common immunostain used in gastrointestinal pathology and genitourinary pathology.
Positive
- Hepatocellular carcinoma.[2]
- Malignant melanoma.[2]
- Squamous cell carcinoma of the lung.[2]
- Uncommon in adenocarcinoma of the lung ~3% of cases.[3]
- Yolk sac tumour.
- More sensitive than alpha-fetoprotein (AFP).[4]
Images
Positive or negative
See also
References
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 300037
- ↑ 2.0 2.1 2.2 2.3 Aydin, O.; Yildiz, L.; Baris, S.; Dundar, C.; Karagoz, F. (2015). "Expression of Glypican 3 in low and high grade urothelial carcinomas.". Diagn Pathol 10: 34. doi:10.1186/s13000-015-0266-4. PMID 25896897.
- ↑ Yu, X.; Li, Y.; Chen, SW.; Shi, Y.; Xu, F. (Aug 2015). "Differential expression of glypican-3 (GPC3) in lung squamous cell carcinoma and lung adenocarcinoma and its clinical significance.". Genet Mol Res 14 (3): 10185-92. doi:10.4238/2015.August.28.2. PMID 26345955.
- ↑ Emerson, RE.; Ulbright, TM. (Jun 2010). "Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers.". Pathology 42 (4): 344-55. doi:10.3109/00313021003767355. PMID 20438407.